Patients' DMT Decision-Making

Volume 2, Issue 4

Patients' DMT Decision-Making

In this issue:

How does a patient choose which DMT to start on? Switch to? Discontinue? What do patients with MS need to know about common comorbidities to minimize their contribution to disease progression? What evidence-based measures can clinicians take to provide the most effective care?

In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, brings recent findings about patient decision-making and addressing common comorbidities into the MS clinic.

Learning objectives:

Discuss the communications issues that influence patients’ disease-modifying therapy decision-making.
Describe potential strategies for addressing comorbidities in the clinical care of individuals with MS.

Author:

Ellen Mowry, MD

Associate Professor
Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Guest Faculty Disclosures

Dr. Mowry has disclosed that she was a principal investigator for Biogen Inc., Genzyme Corp., and SunPharma. She has also received royalty fees from UpToDate® and received free medication for a clinical trial from Teva Pharmaceuticals.

Unlabeled/Unapproved Uses

Dr. Mowry has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Program Director:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Unlabeled/Unapproved Uses:

Dr. Mowry has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: April 19, 2019
Expiration date: April 18, 2021

Start Issue